Quick context
Elamipretide
与线粒体心磷脂结合；美国加速批准仅适用于特定罕见疾病。
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
Back to all 64 profiles
Approved medicine特定用途获批
Community protocol · Elamipretide
Elamipretide: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: SS-31 · Forzinity
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Approved medicine
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
Amount status
Only the prescribing information for the exact approved product applies; brands, concentrations and indications are not interchangeable.
Profile evidence level: established.
Timing
Intervals, time of day and missed-dose handling depend on the product and indication.
No individual recommendation.
Cycle/duration
Approved medicines are clinician-managed treatment, not freely designed community cycles.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
No generic calculator
For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.
For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.
Mechanism and research questions
Mitochondrial cardiolipin-binding tetrapeptide
Elamipretide is classified as “Mitochondrial cardiolipin-binding tetrapeptide”. 与线粒体心磷脂结合；美国加速批准仅适用于特定罕见疾病。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
心磷脂结合
这项研究考察某肽如何结合线粒体膜中的一种特殊脂肪分子并支持其稳定性,类似于对受损结构进行修复夹持。测量指标包括细胞应激标志物和线粒体功能。
线粒体肽
研究人员研究某肽如何与细胞的动力工厂——线粒体相互作用,并影响其能量产生。测量指标包括细胞模型中的耗氧量和能量周转。
细胞能量代谢
研究人员研究细胞如何通过线粒体产生和使用能量,类似于测量发动机燃烧燃料的效率。常见测量指标包括细胞模型中的耗氧量和能量输出。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
生物黑客与长寿论坛
用户比较自行组合的肽方案,以期影响衰老过程或能量水平,常常依据血液检测或主观幸福感量表。个人自我实验和营销承诺无法取代对照的长期人体研究。
抗衰老论坛
这里比较生长轴、线粒体和皮肤相关肽的组合方案,目的是影响可见或可感知的衰老迹象,通常经过多年个人记录。关于延缓衰老的轶事和商家广告并非科学证据。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
Adverse effects and risk boundaries
- 能量与线粒体通路遍及多个器官。可能出现疲劳、头痛、循环、代谢或器官特异性影响；长期数据可能有限。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 妊娠/哺乳及严重心脏、肝脏、肾脏或代谢疾病需要针对适应证的专科评估。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 根据研究问题，可测量生命体征、功能能力、乳酸/代谢指标及器官功能；在明确研究之外通常无统一标准。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
证据充分
该加速批准仅涵盖特定适应症。
Published evidence
所述生物学作用已有充分依据,或针对明确产品和用途已有经监管机构审查的大量人体数据。这些结论不能自动套用于其他产品或用途。
艾拉莫肽已获批用于一种严格限定的罕见病,不同于未受监管的MOTS-c。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
特定用途获批
在至少一个司法辖区作为特定适应证的处方活性成分；本网站不提供该产品。
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA: elamipretide accelerated approval
- Primary/technical sourceDailyMed — FORZINITY prescribing information
- Community referenceElamipretide — Peptide Dosing Protocols